These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9454572)

  • 1. P-glycoprotein shows strong catalytic cooperativity between the two nucleotide sites.
    Senior AE; Bhagat S
    Biochemistry; 1998 Jan; 37(3):831-6. PubMed ID: 9454572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catalytic mechanism of P-glycoprotein.
    Senior AE
    Acta Physiol Scand Suppl; 1998 Aug; 643():213-8. PubMed ID: 9789563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of the "occluded nucleotide conformation" of P-glycoprotein in the catalytic pathway.
    Tombline G; Muharemagić A; White LB; Senior AE
    Biochemistry; 2005 Sep; 44(38):12879-86. PubMed ID: 16171403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stoichiometry and affinity of nucleotide binding to P-glycoprotein during the catalytic cycle.
    Qu Q; Russell PL; Sharom FJ
    Biochemistry; 2003 Feb; 42(4):1170-7. PubMed ID: 12549939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug binding and nucleotide hydrolyzability are essential requirements in the vanadate-induced inhibition of the human P-glycoprotein ATPase.
    Rao US
    Biochemistry; 1998 Oct; 37(42):14981-8. PubMed ID: 9778376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proximity of the nucleotide binding domains of the P-glycoprotein multidrug transporter to the membrane surface: a resonance energy transfer study.
    Liu R; Sharom FJ
    Biochemistry; 1998 May; 37(18):6503-12. PubMed ID: 9572868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains.
    Liu R; Sharom FJ
    Biochemistry; 1996 Sep; 35(36):11865-73. PubMed ID: 8794769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both P-glycoprotein nucleotide-binding sites are catalytically active.
    Urbatsch IL; Sankaran B; Bhagat S; Senior AE
    J Biol Chem; 1995 Nov; 270(45):26956-61. PubMed ID: 7592942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of P-glycoprotein ATPase activity by procedures involving trapping of nucleotide in catalytic sites.
    Sankaran B; Bhagat S; Senior AE
    Arch Biochem Biophys; 1997 May; 341(1):160-9. PubMed ID: 9143365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state.
    Ramachandra M; Ambudkar SV; Chen D; Hrycyna CA; Dey S; Gottesman MM; Pastan I
    Biochemistry; 1998 Apr; 37(14):5010-9. PubMed ID: 9538020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residues in P-glycoprotein catalytic sites that react with the inhibitor 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole.
    Senior AE; Gros P; Urbatsch IL
    Arch Biochem Biophys; 1998 Sep; 357(1):121-5. PubMed ID: 9721190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site.
    Urbatsch IL; Sankaran B; Weber J; Senior AE
    J Biol Chem; 1995 Aug; 270(33):19383-90. PubMed ID: 7642618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FRET analysis indicates that the two ATPase active sites of the P-glycoprotein multidrug transporter are closely associated.
    Qu Q; Sharom FJ
    Biochemistry; 2001 Feb; 40(5):1413-22. PubMed ID: 11170469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of P-glycoprotein ATPase activity by beryllium fluoride.
    Sankaran B; Bhagat S; Senior AE
    Biochemistry; 1997 Jun; 36(22):6847-53. PubMed ID: 9184168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulator-induced interference in functional cross talk between the substrate and the ATP sites of human P-glycoprotein.
    Maki N; Moitra K; Silver C; Ghosh P; Chattopadhyay A; Dey S
    Biochemistry; 2006 Feb; 45(8):2739-51. PubMed ID: 16489767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The catalytic cycle of P-glycoprotein.
    Senior AE; al-Shawi MK; Urbatsch IL
    FEBS Lett; 1995 Dec; 377(3):285-9. PubMed ID: 8549739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in either nucleotide-binding site of P-glycoprotein (Mdr3) prevent vanadate trapping of nucleotide at both sites.
    Urbatsch IL; Beaudet L; Carrier I; Gros P
    Biochemistry; 1998 Mar; 37(13):4592-602. PubMed ID: 9521779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of protection by MgADP and MgATP of α3β3γ subcomplex of thermophilic Bacillus PS3 βY341W-mutant F1-ATPase from inhibition by 7-chloro-4-nitrobenz-2-oxa-1,3-diazole support a bi-site mechanism of catalysis.
    Milgrom YM
    Biochemistry (Mosc); 2011 Nov; 76(11):1253-61. PubMed ID: 22117552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids.
    Eckford PD; Sharom FJ
    Biochem J; 2005 Jul; 389(Pt 2):517-26. PubMed ID: 15799713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of P-glycoprotein ATPase by analogues of tetramethylrosamine: coupling of drug binding at the "R" site to the ATP hydrolysis transition state.
    Tombline G; Donnelly DJ; Holt JJ; You Y; Ye M; Gannon MK; Nygren CL; Detty MR
    Biochemistry; 2006 Jul; 45(26):8034-47. PubMed ID: 16800628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.